In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and ...

A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Notably, FGFR2 expression in murine precancerous lesions correlated with an increase in mutant KRAS signaling. "We know that precancerous pancreatic lesions often carry KRAS mutations," said Tonelli.

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers The preclinical study has implications for pancreatic cancer interception efforts Peer-Reviewed Publication ...

Researchers have identified a new mechanism to delay KRAS-mutated pancreatic cancer development in mice.

Scientists have found a way to 'intercept' pancreatic cancer. By inhibiting the cancer gene FGFR2, they were able to slow tumor formation. By targeting the FGFR2 and EGFR proteins, they were able ...

With the aim of overcoming drug resistance and reducing the toxicities associated with pan-fibroblast growth factor receptor (FGFR) inhibitors, scientists from 3H Pharmaceuticals Co. Ltd. developed a ...

It's the driving oncogene in this disease. We discovered that another gene, FGFR2, plays a role in enhancing mutant KRAS signaling in pancreatic cancer.

Title:Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study ...

With the aim of overcoming drug resistance and reducing the toxicities associated with pan-fibroblast growth factor receptor (FGFR) inhibitors, scientists from 3H Pharmaceuticals Co. Ltd. developed a ...